Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | — | $11.0K | $181K | $374K | $155K | $14.0K | $50.0K |
| Revenue growth | — | — | — | — | 1545.5% | 106.6% | -58.6% | -91.0% | 257.1% |
| Operating income | -$981K | -$12.4M | -$7.76M | -$12.2M | -$29.2M | -$26.0M | -$29.7M | -$42.6M | -$47.4M |
| Operating margin | — | — | — | -111163.6% | -16106.6% | -6938.8% | -19187.7% | -304535.7% | -94766.0% |
| Net income | -$831K | -$12.4M | -$7.68M | -$12.1M | -$30.3M | -$27.3M | -$30.0M | -$42.1M | -$45.9M |
| Net margin | — | — | — | -109990.9% | -16762.4% | -7299.2% | -19360.0% | -300585.7% | -91866.0% |
| EPS (diluted) | -$0.13 | -$1.43 | -$0.75 | -$1.01 | -$1.88 | -$1.52 | -$1.67 | -$2.11 | -$1.86 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$762K | -$2.06M | -$5.38M | -$8.94M | -$28.5M | -$22.7M | -$12.0M | -$33.4M | -$22.6M |
| Capital expenditures | — | — | — | — | — | — | — | — | $1.04M |
| Free cash flow | — | — | — | — | — | — | — | — | -$23.6M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.37M | $186K | $7.00M | $22.0M | $74.8M | $52.2M | $35.8M | $20.9M | $24.8M |
| Total assets | $18.4M | $17.4M | $24.5M | $40.7M | $99.9M | $81.8M | $57.0M | $39.6M | $32.4M |
| Total liabilities | $310K | $824K | $861K | $1.90M | $19.7M | $21.7M | $18.9M | $7.46M | $8.83M |
| Long-term debt | — | — | — | — | $15.0M | $15.0M | — | $15.0M | — |
| Shareholders' equity | $18.1M | $16.5M | $23.6M | $38.8M | $80.2M | $60.1M | $37.3M | $32.1M | $23.5M |
| Retained earnings | -$1.16M | -$13.6M | -$21.3M | -$33.4M | -$63.7M | -$91.0M | -$121M | -$163M | -$209M |
| Shares (wtd avg diluted) | 8.32M | 8.72M | 10.8M | 13.5M | 16.1M | 17.9M | 18.0M | 19.9M | 24.8M |
Every figure is extracted from Inmune Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.